Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | The future of immuno-oncology

Jérôme Galon • 14 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases

Jérôme Galon, MD, PhD, Inserm, Paris, France, talks on the future of immuno-oncology, highlighting the importance of immunotherapies in precision medicine and the recently developed Immunoscore® assay. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Jérôme Galon

2:25
The prognostic value of memory T-cell reactions
Jérôme Galon • 14 Oct 2021
1:20
The cancer immune contexture
Jérôme Galon • 14 Oct 2021
1:36
Immunoscore®: classifying patients based on immune characteristics
Jérôme Galon • 14 Oct 2021
1:44
Immune escape mechanisms in human cancers
Jérôme Galon • 14 Oct 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals